 |
 |
News on nerve growth factor development. I had the pleasure of meeting several key Amgen executives at the PDF Gala a few weeks ago. They are enthusiastic about these compounds, now in phase I trials in Europe. ------------------------- Article ------------------------- Thursday, December 9, 1999 10:31 AM <!--TEXT--> BALTIMORE (Dow Jones)--Guilford Pharmaceuticals Inc. (GLFD) received a $5 million milestone payment from Amgen Inc. (AMGN) for clinical developments in the companies' neuroimmunophilin collaboration. In a press release Thursday, Guilford said it earned the payment when Amgen filed an Investigational New Drug application in the U.S. for the ligands, which have demonstrated, in animal testing, the ability to promote re-growth and repair of damaged nerves. The companies seek to develop neuroimmunophilin ligands for Parkinson's disease, Alzheimer's disease, stroke, peripheral neuropathies, traumatic brain injuries, traumatic spinal cord injuries, multiple sclerosis, ophthalmic applications, and two additional undisclosed nonneurological indications. Under their agreement, Guilford is receiving $13.5 million in research funding over three years, will receive royalties on any future product sales and is eligible to receive up to $392 million in development milestones. Amgen is responsible for conducting all clinical development, manufacturing and marketing. -Michael Squires; Dow Jones Newswires; 201-938-5400 1999 Dow Jones & Company, Inc. All Rights Reserved. ----------------------------------------------------------- This article is produced by Quicken.com, the objective source for making the most of your money. Visit http://www.quicken.com the next time you need financial news, stock quotes, portfolio services, or information about taxes, mortgages, and insurance.